Mouse Models of Myeloid Malignancies.

Mouse models of human myeloid malignancies support the detailed and focused investigation of selected driver mutations and represent powerful tools in the study of these diseases. Carefully developed murine models can closely recapitulate human myeloid malignancies in vivo, enabling the interrogation of a number of aspects of these diseases including their preclinical course, interactions with the microenvironment, effects of pharmacological agents, and the role of non-cell-autonomous factors, as well as the synergy between co-occurring mutations. Importantly, advances in gene-editing technologies, particularly CRISPR-Cas9, have opened new avenues for the development and study of genetically modified mice and also enable the direct modification of mouse and human hematopoietic cells. In this review we provide a concise overview of some of the important mouse models that have advanced our understanding of myeloid leukemogenesis with an emphasis on models relevant to clonal hematopoiesis, myelodysplastic syndromes, and acute myeloid leukemia with a normal karyotype.

• Publication year

  2020

• Venue

  Cold Spring Harbor Perspectives in Medicine

• Publication date

  2020-02-18

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/cshperspect.a035535PMID 32071146PMCID PMC7778217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Myeloid Leukemia

  2020cited by this paper
• A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies

  2019cited by this paper
• Targeting FLT3 mutations in AML: review of current knowledge and evidence

  2019cited by this paper
• Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis

  2019cited by this paper
• UTX Mutations in Human Cancer.

  2019cited by this paper
• Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

  2019cited by this paper
• A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.

  2019cited by this paper
• The role of 3D genome organization in development and cell differentiation

  2019cited by this paper
• Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.

  2019cited by this paper
• UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs

  2018cited by this paper
• Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia

  2018cited by this paper
• Mouse models in the era of large human tumour sequencing studies

  2018cited by this paper
• Rational Design of Mouse Models for Cancer Research.

  2018cited by this paper
• The “Never-Ending” Mouse Models for MLL-Rearranged Acute Leukemia Are Still Teaching Us

  2018cited by this paper
• Somatic mutations precede acute myeloid leukemia years before diagnosis

  2018cited by this paper
• Prediction of acute myeloid leukaemia risk in healthy individuals

  2018cited by this paper
• Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management

  2018cited by this paper
• Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.

  2017cited by this paper
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  2017cited by this paper
• The MLL recombinome of acute leukemias in 2017

  2017cited by this paper
• Overview of the Use of Murine Models in Leukemia and Lymphoma Research

  2017cited by this paper
• Cohesin mutations: contributors to myeloid malignancies

  2017cited by this paper
• Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

  2017cited by this paper
• Novel epigenetic therapies in hematological malignancies: Current status and beyond.

  2017cited by this paper
• Mouse models of MLL leukemia: recapitulating the human disease.

  2017cited by this paper
• Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.

  2017cited by this paper
• p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.

  2017cited by this paper
• Cohesin Mutations in Myeloid Malignancies.

  2017cited by this paper
• Therapy-related myeloid neoplasms: when genetics and environment collide

  2017cited by this paper
• DNMT3A in Leukemia.

  2017cited by this paper
• Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.

  2017cited by this paper
• Splicing factor gene mutations in hematologic malignancies.

  2017cited by this paper
• The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

  2017cited by this paper
• Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.

  2016cited by this paper
• A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

  2016cited by this paper
• Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

  2016cited by this paper
• DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling

  2016cited by this paper
• The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development

  2016cited by this paper
• Structural Insights into Ring Formation of Cohesin and Related Smc Complexes

  2016cited by this paper
• RNA splicing factors as oncoproteins and tumour suppressors

  2016cited by this paper
• The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition

  2016cited by this paper
• Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts

  2016cited by this paper
• Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.

  2016cited by this paper
• Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis

  2016cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.

  2016cited by this paper
• Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2.

  2016cited by this paper
• Therapeutic targeting of splicing in cancer

  2016cited by this paper
• The role of mutations in the cohesin complex in acute myeloid leukemia

  2016cited by this paper
• Mutations in AML: prognostic and therapeutic implications.

  2016cited by this paper
• An oncogenic Ezh2 mutation cooperates with particular genetic alterations to induce tumors in mice and redistributes H3K27 trimethylation throughout the genome

  2016cited by this paper
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.

  2016cited by this paper
• Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.

  2015cited by this paper
• Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains

  2015cited by this paper
• Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis

  2015cited by this paper
• Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

  2015cited by this paper
• High-throughput functional genomics using CRISPR–Cas9

  2015cited by this paper
• Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation.

  2015cited by this paper
• Regulation of the Epigenome by Vitamin C.

  2015cited by this paper
• SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition.

  2015cited by this paper
• Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner.

  2015cited by this paper
• Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms

  2015cited by this paper
• Preclinical mouse cancer models: a maze of opportunities and challenges.

  2015cited by this paper
• Leukemia-Associated Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis

  2015cited by this paper
• Age-related clonal hematopoiesis associated with adverse outcomes.

  2014cited by this paper
• Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

  2014cited by this paper
• Age-related cancer mutations associated with clonal hematopoietic expansion

  2014cited by this paper
• The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

  2014cited by this paper
• NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.

  2014cited by this paper
• Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

  2014cited by this paper
• Translational implications of somatic genomics in acute myeloid leukaemia.

  2014cited by this paper
• Subclonal variant calling with multiple samples and prior knowledge

  2014cited by this paper
• DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through disturbing gene expression/DNA methylation in hematopoietic cells

  2014cited by this paper
• NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.

  2014cited by this paper
• Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation.

  2014cited by this paper
• Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications

  2014cited by this paper
• Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

  2013cited by this paper
• Somatic mutations of calreticulin in myeloproliferative neoplasms.

  2013cited by this paper
• Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype

  2013cited by this paper
• EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

  2013cited by this paper
• The clinical relevance of cancer cell lines.

  2013cited by this paper
• Clinical and biological implications of driver mutations in myelodysplastic syndromes.

  2013cited by this paper
• Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

  2013cited by this paper
• Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

  2013cited by this paper
• Mutational landscape of AML with normal cytogenetics: biological and clinical implications.

  2013cited by this paper
• NPMc+ and FLT3_ITD mutations cooperate in inducing acute leukaemia in a novel mouse model

  2013cited by this paper
• Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

  2013cited by this paper
• Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

  2013cited by this paper
• Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease

  2013cited by this paper
• Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library

  2013cited by this paper
• Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition

  2013cited by this paper
• Genetic Screens in Human Cells Using the CRISPR-Cas9 System

  2013cited by this paper
• The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model.

  2013cited by this paper
• A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice

  2013cited by this paper
• FLT3-ITDs Instruct a Myeloid Differentiation and Transformation Bias in Lymphomyeloid Multipotent Progenitors

  2013cited by this paper
• The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans.

  2012cited by this paper
• IDH mutation impairs histone demethylation and results in a block to cell differentiation

  2012cited by this paper
• Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.

  2012cited by this paper
• The origin and evolution of mutations in acute myeloid leukemia.

  2012cited by this paper

• Inflammatory signaling in the pathogenesis of acute myeloid leukemia

  2025cites this paper
• “Next top” mouse models advancing CTCL research

  2024cites this paper
• In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice

  2023cites this paper
• Aged healthy mice acquire clonal hematopoiesis mutations

  2021cites this paper
• Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS

  2021cites this paper
• Syndromes myélodysplasiques et leucémies secondaires : généralités, diagnostic et classification

  2021cites this paper
• In vivo CRISPR/Cas9 screening identi fi es Pbrm1 as a regulator of myeloid leukemia development in mice

  year unknowncites this paper